CASE CCC IN THE NEWS
Design of Cleveland Clinic's New Cancer Institute Packs a Subtle Precision and Clarity
The Plain Dealer - Sept 27, 2014
The Cleveland Clinic's newest architectural project, a $276 million Cancer Institute, certainly qualifies as a big addition to the institution and the city...Rawn worked with Dr. Brian Bolwell, chairman of the Taussig Institute and his principal client on the project, to design treatment clusters in which doctors and nurses will specialize in various aspects of cancer care.
Cleveland Clinic, UH Share in $1 Million Donation from Cohen Family for Cancer Genomics
The Plain Dealer - Sept 24, 2014
A Shaker Heights family has donated $1 million to the city's largest hospitals to help advance cancer genomics " the method of studying the genes of cancer patients to help improve and personalize their care. The Cleveland Clinic and University Hospitals will share the gift from the family of Joanne and Margaret Cohen, which establishes the Rosalie and Morton Cohen Family Memorial Genomics Fund at each institution.
The Cohens' parents, the late Morton and Rosalie Cohen, made a $1.5 million gift to the UH Seidman Cancer Center in 2007 to establish the Rosalie and Morton A. Cohen Chair in Lung Cancer in honor of UH Seidman Cancer Center President Dr. Nathan Levitan, who cared for Rosalie Cohen during a long treatment for lung cancer.
"This generous gift from the Cohen family provides a unique opportunity for us to support the entire region," said Dr. Brian Bolwell, chairman of the Clinic's Taussig Cancer Institute. "With a large majority of cancer patients in Northeast Ohio being seen at either a Cleveland Clinic or University Hospitals facility, we are uniquely positioned to make a significant impact in this new era of cancer care and research."...
"Genomics is the new frontier of cancer research and the Cohen family's gift will help the Cleveland cancer research community to make further advancements in this rapidly growing field," Dr. Stan Gerson, director of the UH Seidman Cancer Center and the Case Comprehensive Cancer Center at Case Western Reserve University, said in a news release.
The Rosalie and Morton Cohen Family Memorial Genomics Fund, which will be divided equally between the Clinic and UH over three years, will be used to expand genomic sequencing access to under-served populations across the region who have some of the highest mortality rates statewide.
Case Western Reserve University on Track to Become No. 1 Synchrotron Lab in World
Newswise - Sept 23, 2014
Case Western Reserve University's synchrotron facility at Brookhaven National Laboratory is on its way to becoming the No. 1 beamline facility for biology in the world by early 2016, thanks to a jumpstart grant of $4.6 million from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), a component of the National Institutes of Health (NIH)..."When NSLS-II opens, the lab's beamlines will have the brightest, most intense x-ray beams — 100 times brighter than beamlines anywhere in the world," said Mark Chance, PhD, director of the Center for Proteomics and Bioinformatics, Case Western Reserve University School of Medicine. "With this technology, NSLS-II will collect data 100 times faster than any other synchrotron facility in the world."
MARK YOUR CALENDARS
Quality of Life Research Seminar
Register today to attend a Quality of Life Research Seminar,Statistical and Methodological Strategies in Quality of Life Studies, on October 8, 8:45 - 10:15 am in the Wolstein Research Building Auditorium. Presenter Dr. Diane Fairclough is renowned for her research in Quality of Life, outcomes in palliative/hospice care, and psychosocial sequelae of cancer and its therapy in pediatric and adult patients. Her statistical research interests include the analysis of longitudinal studies with non-random missing data due to disease morbidity or mortality. Dr. Fairclough is past president of the International Society for Quality of Life Research, has over 200 peer-reviewed publications, and is the author of Design and Analysis of Quality of Life Studies in Clinical Trials, 2nd edition (2010).
Fall 2014 Case CCC Clinical Research Retreat
The Case CCC will be holding a Clinical Research Retreat on October 7 in the Wolstein Research Building. A reception will be held from 5-5:30 pm, followed by presentations from 5:30-7 pm.
The agenda will focus on the theme of Immunotherapy:
James Finke, PhD: Strategies to Reduce Immune Suppression as a Means to Improve Immunotherapy: A laboratory perspective
Joseph Baar, MD: Recent Advances in the Immunotherapy of Cancer
Shaveta Vinayak, MD: Tumor Infiltrating Lymphocytes Predict for Response to Therapy in Triple-negative Breast Cancer
Mitchell Machtay, MD: National Clinical Trials Network/Cooperative Groups (NCTN) Update
2014 Adolescent and Young Adult Cancers Symposium
This first Adolescent and Young Adult (AYA) cancer conferencehosted by the Case Comprehensive Cancer Center is being held October 30-31 at the Iris S. & Bert L. Wolstein Research Building. This collaborative symposium is organized by the Angie Fowler Adolescent & Young Adult Cancer Institute at University Hospitals Rainbow Babies & Children's Hospital, UH Seidman Cancer Center, Case Comprehensive Cancer Center, and the Oregon Health & Science University Knight Cancer Institute. The focus of this two-day symposium is on advancement of AYA-related cancer research, including exploration of scientific, clinical and psychological considerations in adolescent and young adult cancer patients.
The symposium features speakers from leading academic institutions and non-profit organizations who are at the forefront of AYA research and advocacy, including Heidi Adams, CEO of Critical Mass, and Simon Davies, CEO of Teen Cancer America. We are excited to feature two key speakers from University Hospitals Case Medical Center, Dr. Henry Koon, Disease Team Leader of Melanoma and Dr. Cheryl Kingsberg, Division Chief Ob/GYN Behavioral Medicine, CWRU Obstetrics and Gynecology, University Hospitals MacDonald Women's Hospital.
The symposium also features a keynote address by Clifton Leaf, Deputy Managing Editor, "Fortune Magazine," and author, "The Truth in Small Doses: Why We're Losing the War on Cancer And How to Win It." Mr. Leaf is a cancer survivor and a national advocate for change to the way the global cancer fight is funded and pursued, pushing for ways to speed up progress against the disease. Mr. Leaf has presented testimony to the President's Cancer Panel three times, given a plenary address at the annual meeting of the American Association for Cancer Research, and delivered Grand Rounds at the National Cancer Institute, the only journalist to be given that honor.
We hope that you will join us this year for our first AYA cancer conference, and we hope that we can help you connect to an international community of researchers and advocates for the AYA cancer community. Register today! Continuing Medical Education credits are available.
Support of Case CCC Scientific Program Projects
Proposals are requested from the Case CCC Scientific Programsaddressing unique research opportunities, innovative ideas or areas identified as strategically important to the program. Proposals must be for projects that are aligned with the goals described in the Cancer Center Strategic Plan. They may build on the institutional investments in genomics and informatics, drug screening and discovery, promote the development and use of new technologies, foster new collaborations or strengthen existing research teams through the development of new research areas aligned with the scientific program strategic plan. Attention to catchment area related research is preferred. Proposals should be multi-investigator in nature, with inclusion of translational or clinical research projects.
Each program is asked to submit one response to this RFA.Program leaders must be engaged in identifying potential areas or recommending topics and proposals for the program. Proposals must be reviewed by a committee within the program that is convened specifically for this purpose before being submitted to the Cancer Center Executive Committee. The Executive Committee will make the final determination for funding after evaluating proposals and reviews. It is expected that the research projects will lead to nationally competitive grant proposals from multi-investigator teams.
Deadline for Submission to Program Leaders: November 7
Deadline for Submission of priority proposals to Executive Committee: December 15
Alex's Lemonade Stand Foundation Innovation Grant
Alex's Lemonade Stand Foundation (ALSF) is committed to creating opportunities for new and innovative research into treatments and cures for childhood cancers. Innovation grantsare designed as seed funding for researchers with a novel approach to pediatric oncology scientific investigation. This may represent a change in research direction and/or an innovative new idea that moves away from an investigator's prior research but has potential impact for childhood cancers. Innovation Grants will support research proposals to be carried out by investigators who are already established, have a track record of peer-reviewed publications and evidence of successfully competing for extramural funding. The grant is for two years up to $125,000 per year. A one year no cost extension is encouraged.
LOI Deadline: December 3
Support of Multi-investigator Initiatives in the Case CCC
The Case CCC will provide two modes of support to new research teams that plan to submit large multi-investigator grant applications (usually non-R support mechanisms).
- Administrative support and funding for travel are available to encourage team member meetings and meetings with external advisors.
- Pilot project funding for research teams with an established track record of collaborative research is available to support key research initiatives that are necessary to generate competitive multi-investigator proposals.
Requests are competitive. The research team must demonstrate the active engagement of members, clearly articulate the significance and innovation of the project, and provide a roadmap for acquisition of external funding. Advocacy and support of the specific program leadersinteracting with the team is required. Discussion with Ruth Keri, PhD, Associate Director for Basic Research, is strongly encouraged before developing an application.
HELP US HELP YOU!
If you have a new grant, recently won an award, or have other newsworthy items, please let us know so we can publicize them in the newsletter and other media outlets. You deserve the accolades! Send items to Gillian Irwin at firstname.lastname@example.org.